The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
COMy 2020 | The importance of treating multiple myeloma patients during the COVID-19 pandemic
Graham Jackson, MBBS, FRCP, FRCPath, MD, Newcastle upon Tyne Hospitals NHS Trust, Newcastle, UK, discusses how multiple myeloma patients are affected by the COVID-19 infection. A study in the UK, that Prof. Jackson was involved in, indicated that active disease was associated with severe COVID-19 infection. Another international study found similar results. It has not been shown that treatment with immunomodulators, proteasome inhibitors, anti-CD38 antibodies or transplantation is related to increased COVID-19 infection. Therefore, the treatment of myeloma patients should not be delayed to give patients the best chance of survival during the pandemic. This interview took place during the Controversies in Multiple Myeloma (COMy) 2020 Virtual World Congress.
Disclosures
Advisory boards: GSK, Takeda, celgene/BMS, Amgen, Oncopeptides, Sanofi, Janssen
Speakers bureau: GSK, Takeda, celgene/BMS, Amgen, Janssen
Research: Celgene/BMS, Takeda, Onyx
